Circulating angiotensin-converting enzyme 2 activity in kidney transplantation: A longitudinal pilot study

Nephron - Clinical Practice

Volumn 121, Issue 3-4, 2013, Pages

  Soler, María José ^a   Riera, Marta ^a   Crespo, Marta ^a   Mir, Marisa ^a   Márquez, Eva ^a   Pascual, María José ^a   Puig, Josep M ^a   Pascual, Julio ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Angiotensin converting enzyme 2; Graft function; Kidney transplant; Renin angiotensin system

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ASPARTATE AMINOTRANSFERASE; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA GLUTAMYLTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; UREA;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FLUORESCENCE ANALYSIS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; SEX DIFFERENCE; UREA BLOOD LEVEL;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PILOT PROJECTS; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SPAIN; YOUNG ADULT;

EID: 84871204126     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000345508     Document Type: Article

References (26)

1. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G: Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451-457.
2. Moreso F, Calvo N, Pascual J, Anaya F, Jimenez C, Del Castillo D, et al: Early statin use is an independent predictor of long-term graft survival. NDT Plus 2010; 3(suppl 2):ii26-ii31.
3. Pastan S, Bailey J: Dialysis therapy. N Engl J Med 1998; 338: 1428-1437.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
5. Stigant CE, Cohen J, Vivera M, Zaltzman JS: ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35: 58-63. (Pubitemid 30027241)
6. Calvino J, Lens XM, Romero R, Sanchez-Guisande D: Long-term anti-proteinuric effect of losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 2000; 15: 82-86. (Pubitemid 30037935)
7. Holgado R, Anaya F, Del Castillo D: Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16(suppl 1):117-120. (Pubitemid 32492522)
8. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1-E9.
9. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM: Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin- converting enzyme 2, and neprilysin in a family study. Hypertension 2006; 48: 914-920. (Pubitemid 44611005)
10. Lew RA, Warner FJ, Hanchapola I, Yarski MA, Manohar J, Burrell LM, et al: Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008; 93: 685-93. (Pubitemid 351595050)
11. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S: Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counterregulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 2008; 52: 750-754.
12. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838-14843. (Pubitemid 34952556)
13. Schwager SL, Carmona AK, Sturrock ED: A high-throughput fluorimetric assay for angiotensin I-converting enzyme. Nat Protoc 2006; 1: 1961-964. (Pubitemid 46773318)
14. Batlle D, Soler MJ, Wysocki J: New aspects of the renin-angiotensin system: angiotensinconverting enzyme 2-a potential target for treatment of hypertension and diabetic nephropathy. Curr Opin Nephrol Hypertens 2008; 17: 250-257. (Pubitemid 351535927)
15. Soler MJ, Wysocki J, Batlle D: Angiotensinconverting enzyme 2 and the kidney. Exp Physiol 2008; 93: 549-556.
16. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D: ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocininduced diabetic mice. Kidney Int 2007; 72: 614-623. (Pubitemid 47312795)
17. Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D: Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol 2009; 296:F398-F405.
18. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, et al: ACE and ACE2 activity in diabetic mice. Diabetes 2006; 55: 2132-2139. (Pubitemid 44509989)
19. Soro-Paavonen A, Gordin D, Forsblom C, Rosengard-Barlund M, Waden J, Thorn L, et al: Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 2012;30:375-383.
20. Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, et al: ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008; 57: 1018-1025.
21. Yamaleyeva LM, Gilliam-Davis S, Almeida I, Brosnihan KB, Lindsey SH, Chappell MC: Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2. Lewis rats with early onset diabetes. Am J Physiol Renal Physiol 2012; 302:F1374-F1384.
22. Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY: Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 2008; 172: 1174-1183. (Pubitemid 351671532)
23. Soler MJ, Barrios C, Oliva R, Batlle D: Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep 2008; 10: 410-414.
24. Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, et al: Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin-converting enzyme 2. Gut 2005; 54: 1790-1796. (Pubitemid 41697680)
25. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, et al: Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889-899.
26. Lopez V, Martin M, Cobelo C, Aranda P, Cabello M, Sola E, et al: Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients. Transplant Proc 2010; 42: 2883-2885.